Diphenylpyraline Hydrochloride

CHEMBL1564 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
317.9 g/mol
LogP
Phase
4

A hydrochloride salt form of diphenylpyraline with the same antihistamine properties used to treat allergic conditions. It relieves symptoms by blocking the effects of histamine in the body.

Molecular Weight

317.9000 g/mol

TPSA

12.50 Ų

Mechanism of Action

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCC(OC(c2ccccc2)c2ccccc2)CC1.Cl

InChI

InChI=1S/C19H23NO.ClH/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17;/h2-11,18-19H,12-15H2,1H3;1H

Molecular Formula

C19H24ClNO

HBD / HBA

1 / 2

Rotatable Bonds

4

Heavy Atoms

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A hydrochloride salt form of diphenylpyraline with the same antihistamine properties used to treat allergic conditions. It relieves symptoms by blocking the effects of histamine in the body.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Diphenylpyraline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1564. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 66063. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.